Dirk Sibbing Shares Phase 3 Study on Dissaggpro for STEMI – Rapid Onset and Fast Offset of Antiplatelet Action!
Dirk Sibbing, Professor, Cardiologist and Angiologist at Lauterbacher Mill Private Clinic and LMU Munich, shared on LinkedIn:
”A new drug on the horizon for pre-hospital treatment of STEMI patients
Subcutaneous GPIIb/IIIa – Dissaggpro
Rapid onset and fast offset of antiplatelet action
Phase 3 Study (CeleBrate) of Novel Anti-Platelet Drug for Heart Attack Reports Positive Topline Results as announced by CeleCor Therapeutics
This, for sure, will bring new aspects into the discussions on pretreatment (antiplatelet) for STEMI patients…
Still we are loosing too many patients pre-hospital and before we see them in the cath lab…
Results will be presented as LBCT at AHA 2025 in New Orleans
Arnoud van ‘t Hof, Robert S. Hillman, Jur ten Berg, C. Michael Gibson, M.S., M.D.”
Read the full article here.
Article: Phase 3 Study of Novel Anti-Platelet Drug for Heart Attack Reports Positive Topline Results
Stay updated on all scientific advances in the field with Hemostasis Today.
-
Jul 2, 2026, 10:58Heghine Khachatryan: What Is Your Position on the Voluntary or Financially Compensated Blood Donation Model
-
Jul 2, 2026, 10:51Faces of Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
-
Jul 2, 2026, 10:44Priya Sriskandarajah: Understanding Anemia of Chronic Disease in Clinical Practice
-
Jul 2, 2026, 10:42Flora Peyvandi: Germline-Targeting Vaccines for HIV
-
Jul 2, 2026, 10:29Nisar Ahmed: The Evolution of Anticoagulation Therapy
-
Jul 2, 2026, 09:24Paschalis Evangelidis: Presenting Real-World Evidence to Improve Outcomes in TMA at EHA 2026
-
Jul 2, 2026, 09:09Mihaela Cordeanu: Can D-dimer Help Diagnose Splanchnic Vein Thrombosis?
-
Jul 2, 2026, 09:00Abdelrahman Essam: Why Early Hemorrhage Control Is Critical in Pelvic Fractures
-
Jul 2, 2026, 08:40Megan Adediran: Raising Awareness of Haemophilia Risks During Circumcision